NCT05742607 · Innate Pharma
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
(MATISSE)
What this study is about
The study is intended to assess the safety and effectiveness of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
View original scientific description
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Interventions
DRUG
IPH5201 + durvalumab + standard chemotherapy
Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy. In Cohort 1 only, Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.
Primary outcome measures
Pathological Complete Response (pCR)
Time frame: 16 weeks after the first dose of study intervention.
Number of patients with pathological Complete Response (pCR)
Adverse events (AEs) and serious adverse events (SAEs)
Time frame: Until Day 90 after the last dose of study interventions.
Number of patients with adverse events (AEs) and serious adverse events (SAEs).
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Newly diagnosed and previously untreated patients with histologically or cytologically documented NSCLC resectable (Stage IIA to Stage IIIA) disease (according to Version 8 of IASLC Staging Manual in Thoracic Oncology 2016. 2. WHO Performance Status or Eastern Cooperative Oncology Group of 0 or 1. 3. Adequate organ and marrow function. 4. Must have a life expectancy of at least 12 weeks. 5. Body weight \> 35 kg. 6. Females of childbearing potential should use an acceptable method of contraception from the time of screening throughout the total duration of the study. 7. Negative pregnancy test (serum or urine) for women of childbearing potential. 8. Provision of tumor samples (newly acquired \[preferred\] or archival tumor tissue \[≤ 6 months old\]) to confirm Programmed Death-Ligand 1 status, Epidermal Growth Factor Receptor, or Anaplastic Lymphoma Kinase status. 9. Provision of tumor samples appropriate for exploratory biomarker analyses. 10. Patients will be s
Where
- St. Petersburg, Florida
- Tampa, Florida
- Chicago, Illinois
- Lake Success, New York
- Houston, Texas
- Madison, Wisconsin
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 17, 2026 · Source of record for eligibility and locations